PDGFRA exon 14 mutations in GIST are very rare and are imatinib- sensitive. Treatment is...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PDGFRA-EXON14-GIST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GIST |
| Sources | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-PDGFRA |
|---|---|
| Variant | exon 14 mutation (ATP-binding pocket — N659K, N659Y; very rare) |
| Disease | DIS-GIST |
| ESCAT tier | IB |
| Recommended combinations | imatinib 400 mg/day (1L advanced/metastatic) |
| Evidence summary | PDGFRA exon 14 mutations in GIST are very rare and are imatinib- sensitive. Treatment is identical to other imatinib-sensitive PDGFRA variants: imatinib 400 mg/day 1L. Per OncoKB and NCCN, all PDGFRA non-D842V mutations are grouped as imatinib-responsive. |
Notes
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST.
Used By
No reverse references found in the YAML corpus.